Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Ltd, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. Founded in 2017, the company has quickly established itself as a key provider of high-quality products, catering to both domestic and international markets. With a focus on innovation and sustainability, Solara offers a diverse range of APIs, particularly in the therapeutic areas of anti-infectives, cardiovascular, and central nervous system medications. The company’s commitment to quality and regulatory compliance has earned it a strong market position, with notable achievements in securing approvals from major global regulatory bodies. Solara's strategic operational regions extend across Asia, Europe, and the Americas, reinforcing its status as a trusted partner in the pharmaceutical supply chain.
DitchCarbon Score
How does Solara Active Pharma Sciences Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Solara Active Pharma Sciences Ltd's score of 18 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Solara Active Pharma Sciences Ltd's reported carbon emissions
In 2023, Solara Active Pharma Sciences Ltd reported total carbon emissions of approximately 54,428,000 kg CO2e, comprising 11,168,000 kg CO2e from Scope 1 and 43,425,000 kg CO2e from Scope 2. This marked a slight increase from 2022, where emissions were about 51,623,000 kg CO2e, with 10,169,000 kg CO2e from Scope 1 and 50,693,000 kg CO2e from Scope 2. The company has not disclosed any Scope 3 emissions data. Despite the increase in emissions, Solara has not set specific reduction targets or climate pledges, indicating a potential area for improvement in their sustainability strategy. The emissions data is not cascaded from any parent organization, and all figures are reported directly from Solara Active Pharma Sciences Ltd. The company’s emissions intensity for Scope 1 and Scope 2 combined was reported at about 10,890 kg CO2e per tonne of output in 2024, reflecting their operational efficiency in relation to emissions. As of now, there are no documented climate initiatives or commitments to reduce emissions, which places Solara in a context where further action may be necessary to align with industry standards for climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 10,169,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 50,693,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Solara Active Pharma Sciences Ltd is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
